Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | EEF2K | O00418 | 9/20 | 0.37 |
| ▸ | IKBKB | O14920 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090523 | 0.92 | MAPT (0.49) | MAPTMEN1ALDH1A1GAAHPGD | |
| SCHEMBL3655949 | 0.90 | ALDH1A1 (0.34) | MAPTMEN1ALDH1A1GAAHPGD | |
| SCHEMBL3101803 | 0.89 | MAPT (0.49) | MAPTMEN1ALDH1A1GAAHPGD | |
| SCHEMBL3087584 | 0.87 | MAPT (0.52) | MAPTMEN1ALDH1A1GAAHPGD | |
| SCHEMBL3084095 | 0.87 | EEF2K (0.46) | MAPTMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL3095689 | 0.87 | MEN1 (0.51) | MAPTMEN1ALDH1A1GAAHPGD | |
| SCHEMBL3099226 | 0.86 | MEN1 (0.51) | MAPTMEN1ALDH1A1GAAHPGD | |
| SCHEMBL3102085 | 0.83 | EEF2K (0.46) | MAPTMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL3088911 | 0.83 | MAPT (0.48) | MAPTMEN1ALDH1A1GAAHPGD | |
| SCHEMBL3649451 | 0.82 | ALDH1A1 (0.37) | MAPTMEN1ALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| US-8202882-B2 | 5-cyanothienopyridines for the treatment of tumours | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202882-B2 | 5-cyanothienopyridines for the treatment of tumours | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202882-B2 | 5-cyanothienopyridines for the treatment of tumours | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | TGFBR1, TGFBR2, ACVR1 | MAPT 4149/4885MEN1 539/4885ALDH1A1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.